Andy
Retired committee member
Merged thread
Final paper abstract here
************
Editorial: Ferritin and myalgic encephalomyelitis/chronic fatigue syndrome in post COVID-19, an unexpected facet of the hyperferritinemic syndrome?
Coronavirus disease 2019 (COVID-19) has provoked a catastrophic medical emergency worldwide [1]. In the course of time from the beginning of this pandemic, subacute and long-term effects in patients suffering from COVID-19 have been increasingly recognised [1,2]. Thus, the term “long-COVID-19” has been proposed to describe this collection of signs and symptoms which may continue or sometimes develop following the SARS-CoV-2 infection. The latter is defined as post-COVID-19 syndrome [3]. In a large percentage of these patients, mental health problems and fibromyalgia have been also recognised [[3], [4], [5]]. Interestingly, many patients could experience severe fatigue in a clinical setting of myalgic encephalitis/chronic fatigue syndrome (ME/CFS), even several months after SARS-CoV-2 infection [6]. In this context, low level inflammation and hypoperfusion have been recently proposed as potential pathomechanisms of occurrence of ME/CFS [7].
On these bases, possible predictors of ME/CFS have been recently investigated in 234 patients with post-COVID-19 syndrome [8]. To date, almost 60% of evaluated patients had fatigue symptoms, and 21.4% met classification criteria for ME/CFS. The authors performed a deep assessment of laboratory features of included patients, stratifying the results in 3 groups, namely patients meeting classification criteria for ME/CFS, patients with fatigue but not reaching the classification criteria for ME/CFS, and patients without fatigue.
Open access, https://www.sciencedirect.com/science/article/pii/S0022399923000880
Final paper abstract here
************
Editorial: Ferritin and myalgic encephalomyelitis/chronic fatigue syndrome in post COVID-19, an unexpected facet of the hyperferritinemic syndrome?
Coronavirus disease 2019 (COVID-19) has provoked a catastrophic medical emergency worldwide [1]. In the course of time from the beginning of this pandemic, subacute and long-term effects in patients suffering from COVID-19 have been increasingly recognised [1,2]. Thus, the term “long-COVID-19” has been proposed to describe this collection of signs and symptoms which may continue or sometimes develop following the SARS-CoV-2 infection. The latter is defined as post-COVID-19 syndrome [3]. In a large percentage of these patients, mental health problems and fibromyalgia have been also recognised [[3], [4], [5]]. Interestingly, many patients could experience severe fatigue in a clinical setting of myalgic encephalitis/chronic fatigue syndrome (ME/CFS), even several months after SARS-CoV-2 infection [6]. In this context, low level inflammation and hypoperfusion have been recently proposed as potential pathomechanisms of occurrence of ME/CFS [7].
On these bases, possible predictors of ME/CFS have been recently investigated in 234 patients with post-COVID-19 syndrome [8]. To date, almost 60% of evaluated patients had fatigue symptoms, and 21.4% met classification criteria for ME/CFS. The authors performed a deep assessment of laboratory features of included patients, stratifying the results in 3 groups, namely patients meeting classification criteria for ME/CFS, patients with fatigue but not reaching the classification criteria for ME/CFS, and patients without fatigue.
Open access, https://www.sciencedirect.com/science/article/pii/S0022399923000880
Last edited by a moderator: